Apellis And Sobi Announce Phase 3 VALIANT Study Results For Pegcetacoplan In Rare Kidney Diseases; Achieves 68% Reduction In Proteinuria, Consistent Across All Subgroups; Data Submission Planned For US And EU
Portfolio Pulse from Benzinga Newsdesk
Apellis Pharmaceuticals and Sobi announced positive Phase 3 VALIANT study results for Pegcetacoplan in treating rare kidney diseases, achieving a 68% reduction in proteinuria. The results were consistent across all subgroups, and data submission is planned for the US and EU. Apellis will host a conference call at 8:00 AM ET.
August 08, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals announced positive Phase 3 results for Pegcetacoplan, showing a 68% reduction in proteinuria in rare kidney diseases. Data submission is planned for the US and EU.
The positive Phase 3 results for Pegcetacoplan are significant for Apellis Pharmaceuticals, as they demonstrate a substantial reduction in proteinuria, a key marker in kidney diseases. The consistency across all subgroups and the planned data submission for regulatory approval in the US and EU are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100